Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries and the United States.
Exceptional growth potential with flawless balance sheet.
Share Price & News
How has Photocure's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PHO has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: PHO exceeded the Norwegian Pharmaceuticals industry which returned 12.2% over the past year.
Return vs Market: PHO exceeded the Norwegian Market which returned -3.2% over the past year.
Price Volatility Vs. Market
How volatile is Photocure's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 weeks ago | Simply Wall StCompanies Like Photocure (OB:PHO) Can Afford To Invest In Growth
1 month ago | Simply Wall StWhat Kind Of Shareholder Owns Most Photocure ASA (OB:PHO) Stock?
2 months ago | Simply Wall StPhotocure ASA (OB:PHO): Commentary On Fundamentals
Is Photocure undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: PHO (NOK57.6) is trading below our estimate of fair value (NOK340.58)
Significantly Below Fair Value: PHO is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: PHO is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: PHO is unprofitable, so we can't compare its PE Ratio to the Norwegian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PHO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PHO is overvalued based on its PB Ratio (7.4x) compared to the XE Pharmaceuticals industry average (3.1x).
How is Photocure forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PHO is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.8%).
Earnings vs Market: PHO is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: PHO's is expected to become profitable in the next 3 years.
Revenue vs Market: PHO's revenue (28.3% per year) is forecast to grow faster than the Norwegian market (4.3% per year).
High Growth Revenue: PHO's revenue (28.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PHO's Return on Equity is forecast to be very high in 3 years time (44.2%).
How has Photocure performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PHO has high quality earnings.
Growing Profit Margin: PHO's current net profit margins (-10.5%) are higher than last year (-22.1%).
Past Earnings Growth Analysis
Earnings Trend: PHO is unprofitable, and losses have increased over the past 5 years at a rate of -9.8% per year.
Accelerating Growth: Unable to compare PHO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PHO is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (0.9%).
Return on Equity
High ROE: PHO has a negative Return on Equity (-13.63%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is Photocure's financial position?
Financial Position Analysis
Short Term Liabilities: PHO's short term assets (NOK143.5M) exceeds its short term liabilities (NOK39.5M)
Long Term Liabilities: PHO's short term assets (143.5M) exceeds its long term liabilities (10.8M)
Debt to Equity History and Analysis
Debt Level: PHO is debt free.
Reducing Debt: PHO has not had any debt for past 5 years.
Inventory Level: PHO has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if PHO's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable PHO has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: PHO is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 2.4% per year.
What is Photocure's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate PHO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate PHO's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PHO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PHO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: PHO is not paying a notable dividend for the Norwegian market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PHO's dividend in 3 years as they are not forecast to pay a notable one for the Norwegian market.
What is the CEO of Photocure's salary, the management and board of directors tenure and is there insider trading?
Average management tenure
Dan Schneider 0
Mr. Daniel Schneider, also known as Dan, has been President & CEO of PhotoCure ASA since November 1, 2018. He has been Vice President of Sales at Pernix Sleep, Inc. (also known as Somaxon Pharmaceuticals, ...
Management Age and Tenure
Experienced Management: PHO's management team is considered experienced (2.5 years average tenure).
Board Age and Tenure
Experienced Board: PHO's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Grete Hogstad (63yo)
Vice President of Strategic Marketing
- Tenure: 0yrs
- Compensation: kr1.43m
Erik Dahl (62yo)
Chief Financial Officer
- Tenure: 7.3yrs
President & CEO
- Tenure: 1yrs
Gry Stensrud (49yo)
Vice President of Technical Development & Operations
- Tenure: 0yrs
Head of Nordic Cancer Commercial Operations
- Tenure: 7.8yrs
- Tenure: 0yrs
Chief Business Officer
- Tenure: 2.5yrs
Head of Global Medical Affairs & Clinical Development
- Tenure: 0.8yrs
- Tenure: 2.6yrs
Gwen Melincoff (67yo)
- Tenure: 2.6yrs
Tom Pike (59yo)
- Tenure: 5.8yrs
Jan Egberts (61yo)
- Tenure: 2.6yrs
- Tenure: 3.5yrs
- Tenure: 0.4yrs
- Tenure: 0.4yrs
Photocure ASA's company bio, employee growth, exchange listings and data sources
- Name: Photocure ASA
- Ticker: PHO
- Exchange: OB
- Founded: 1997
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: kr1.255b
- Shares outstanding: 21.78m
- Website: https://www.photocure.com
Number of Employees
- Photocure ASA
- Hoffsveien 4
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|PHO||OB (Oslo Bors)||Yes||Ordinary Shares||NO||NOK||Mar 2000|
|PHCU.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Mar 2000|
|0IMT||LSE (London Stock Exchange)||Yes||Ordinary Shares||GB||NOK||Mar 2000|
|PHS||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Mar 2000|
|PHOO||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Ordinary Shares||GB||NOK||Mar 2000|
Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries and the United States. ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2019/11/13 20:33|
|End of Day Share Price||2019/11/13 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.